Carey Megan E, Diaz Zoey I, Broadstock Martin, Bailey Roderick, Bentsi-Enchill Adwoa D, Larson Heidi J
Enteric and Diarrheal Diseases, Global Health, Bill & Melinda Gates Foundation, Seattle, Washington.
Immunology and Vaccines, Medical Research Council, London.
Clin Infect Dis. 2019 Oct 15;69(Suppl 5):S408-S411. doi: 10.1093/cid/ciz483.
With a newly World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible countries, and a WHO policy recommendation for TCV use, now is the time for countries to introduce TCVs as part of an integrated typhoid control program, particularly in light of the increasing burden of antimicrobial resistance. Continued vaccine development efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data and inform optimal deployment strategies, in both routine use and in outbreak settings. TCV programs should include thoughtful communication planning and community engagement to counter vaccine hesitancy.
随着世界卫生组织（WHO）新预认证的伤寒结合疫苗（TCV）、全球疫苗免疫联盟（Gavi）对符合条件国家的资金支持以及WHO对TCV使用的政策建议，各国现在应将TCV作为综合伤寒控制计划的一部分引入，特别是考虑到抗菌药物耐药性负担日益加重的情况。持续的疫苗研发努力将确保低成本疫苗的供应，正在进行的疫苗研究将提供关键的疫苗性能数据，并为常规使用和疫情暴发情况下的最佳部署策略提供信息。TCV计划应包括周全的沟通规划和社区参与，以应对疫苗犹豫问题。
